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Abstract
Objective-To compare responses of patients
with cancer with those of a matched control group,
cancer specialists, general practitioners, and cancer
nurses in assessing personal cost-benefit of chemo-
therapy.
Design-Prospective study of consecutively
recruited patients with cancer and other groups by
questionnaire; half of the patients received the
questionnaire again three months after starting treat-
ment.
Setting-A medical oncology ward of a London
teaching hospital.
Subjects- 106 Patients with newly diagnosed solid
tumours referred to the unit for consideration of
treatment with cytotoxic chemotherapy, 100 ofwhom
were able to complete the questionnaire. 100
Matched controls, 315 cancer doctors (238 radio-
therapists and 77 medical oncologists), 1500
randomly chosen general practitioners, and 1000
randomly chosen cancer nurses.
Main outcome measures-Percentage chance of
cure, prolonging life, or palliation of symptoms
required to make treatment worth while with two
hypothetical chemotherapy treatments, with severe
and mild side effects respectively.
Results-Respondents to the questionnaire
comprised 100 patients, 100 controls, 60 (78%)
medical oncologists, 88 (37%) radiotherapists, 790
(53%) general practitioners, and 303 (30%) cancer
nurses. Most patients were willing to -accept intensive
chemotherapy for a very small chance of benefit.
The median benefit required to make the hypo-
thetical intensive treatments worth while for patients
compared with controls were: for chance of a cure
(range 1 to 100%) 1% v 50%, for prolonging life
(range three months to five years) 12 months v 24-60
months, and for relief ofsymptoms (range 1 to 100%)
10% v 75% respectively. There were no significant
differences in the responses of the 50 patients
completing the questionnaire on a second occasion.
Doctors and nurses were less likely to accept radical
treatment for minimal benefit compared with the
patients (median scores 10-50%, 12-24 months, and
50-75%, for chance of cure, prolonging life, and
relief of symptoms respectively). Significantly more
patients than controls accepted treatments giving
the minimal benefit for each category (cure 53-1 v
19'0%, 67-0 v 35 0%; prolonging life 42-1 v 10-0%,
53 0 v 25 0%; relief of symptoms 42-6 v 10-0%, 58 7 v
19.0% for intensive and mild treatments respectively,
p<0-001) as was the case for comparison of patients
with other groups.
Conclusion-Patients with cancer are much more
likely to opt for radical treatment with minimal
chance of benefit than people who do not have
cancer, including medical and nursing professionals.
This should be taken into account when discussing
treatment options with patients and their relatives.
Introduction
Until fairly recently the general public expected, and
indeed was happy, to leave medical decision making to
doctors. An increasing interest in consumer affairs has
resulted in an awareness that personal responsibility
for health care and participation in medical decision
making are desirable and possible. Several North
American studies have examined participation
preferences. Cassileth et al sought the preferences of
256 patients with cancer.' Most patients in each
age group preferred active participation, although,
generally, younger patients wanted to be more in-
volved. Degner and Russell asked 60 patients with
cancer whether they preferred to "keep, share, or give
away" control over decision making.) Most preferred
the option of shared control, usually with the doctor
rather than a relative.
Increased participation in decision making means
that patients need more information about their disease
and treatment options. This has caused concern among
health care workers, who thought that this might be
depressing for patients.' Cassileth et al found that
patients were able to maintain hope, and in fact were
generally more hopeful, despite having this infor-
mation.' Faden et al showed that doctors' and patients'
opinions differed about the outcome of receiving
information about drug treatment for epilepsy.4
Doctors believed that patients would have less confi-
dence in their drugs ifthey were given more information
whereas patients thought that they would be more
likely to comply with treatments and would have more
confidence in the prescribed drugs and in their doctors
if given more information.
Two studies were conducted by McNeil et al in 1978
and 1981. The first studied patients with stage I or
stage II cancer of the lung who had already received
surgery or radiotherapy. The patients were interviewed
individually about their attitudes to various periods of
survival in hypothetical situations. Of the 14 patients
with cancer who had participated, 12 were "risk
averse" and considered the small chance of early death
during surgery unacceptable. They preferred radio-
therapy despite its lower five year survival rate.
The second study examined the attitudes of healthy
volunteers to quality of life rather than its quantity.
Volunteers had to imagine that they had T3 carcinoma
of the larynx and were asked whether they would
prefer surgery, with its then current higher survival
rate but loss of normal speech, or radiotherapy, with its
lower survival rate but preservation of normal or nearly
normal speech. In this hypothetical situation a fifth
chose radiotherapy.
These North American studies showed that patients'
and doctors' attitudes to treatment options often differ
and that patients may welcome the opportunity to be
included in the decision making process.
Our study examined the treatment preferences of
patients with cancer in a British hospital by question-
naire and compared them with those of a matched
control group, cancer specialists, general practitioners,
and cancer nurses.
Subjects and Methods
QUESTIONNAIRE
We used a questionnaire describing two hypothetical
treatments with chemotherapy: one representing a
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typical intensive chemotherapy regimen and the other
a much milder chemotherapy regimen. The intensive
regimen was said to have a considerable number of side
effects and drawbacks, such as severe nausea and
vomiting, hair loss, frequent use of needles and drips,
frequent tiredness and weakness, admission to hospital
for three or four days a month, decreased sexual
interest (for the period of treatment), and possible
infertility. The mild regimen was said to have fewer
side effects and drawbacks, with only slight nausea and
vomiting, no loss of hair, occasional use of needles and
drips, some tiredness and weakness, and admission to
hospital about once a month.
Subjects were asked to assess their willingness to
have these two treatments in three possible circum-
stances; the first when the treatment offered a chance
of cure, the second when cure was not possible but the
treatment offered the chance of prolonging life, and
the third when treatment was given only to relieve
symptoms.
Patients were asked to rate the possible benefit that
would make acceptance of these treatments worth
while. Thus for the curative treatment they rated what
chance of cure between 1% and 100% would make the
treatment worth while. For the treatment designed to
prolong life they were asked what duration, ranging
from three months to five years, would make this
treatment worth while, and when the treatment was
given to relieve symptoms they were asked tvhat
chance of relieving symptoms, rated from 1% to 100%,
would make this treatment worth while. In all circum-
stances there was an option for saying that the
treatment was unacceptable under any circumstances.
SUBJECTS
Patients-One hundred and six consecutive patients
with solid tumours who were about to receive chemo-
therapy were asked to complete the questionnaire. Six
patients were unable to complete it, three being too
distressed and three being unable to understand the
questions. Of the 100 patients remaining, 41 had small
cell carcinoma of the lung and 59 had other types
of tumour including ovarian carcinoma, cervical
carcinoma, myeloma, and lymphoma. The median age
of the patients was 60 (range 23 to 80), and there was no
significant difference in age between men and women.
The questionnaire was given to patients by a research
nurse, who made it clear that she had no part in
decisions about their treatment. It was given a second
time to half of the patients chosen randomly after they
had completed three cycles of treatment. Two patients
who were approached thought that they could not
repeat the questionnaire because their treatment with
chemotherapy had failed and they were too distressed
to consider a hypothetical situation.
Controls-One hundred controls matched for age,
sex, ethnic origin, and occupation were obtained from
the community. None of them or close members of
their families had cancer or had previously had cancer.
Patients with other diseases and hospital staffwho had
TABLE I-Median scores (representing minimal benefit to make two hypothetical treatments acceptable in
three circumstances) for controls, cancer nurses, general practitioners, cancer doctors, and patients with
cancer
Subject group
Controls Cancer nurses General practitioners Cancer doctors Patients
(n= 100) (n=303) (n=790) (n= 148) (n= 100)
Intensive treatment:
Chance of cure (%) 50 50 25 10 1
Prolonging life (months) 24-60 24 24 12 12
Relief of symptoms (0) 75 50 75 50 10
Mild treatment:
Chance of cure (%) 25 10 10 10 1
Prolonging life (months) 18 12 12 6 3
Relief of symptoms (%) 50 25 25 25 1
direct contact with patients were also excluded from
the control group.
Cancer doctors-The questionnaire was sent to 238
radiotherapists and 77 medical oncologists, together
with a covering letter requesting them to answer the
questions as if they themselves had cancer. Responses
were received from sixty medical oncologists (78%)
and 88 radiotherapists (37%). The medical oncologists
and radiotherapists circulated represented as complete
a list of consultants and senior registrars in these
specialties as could be obtained.
General practitioners-A direct postal company
circulated the questionnaire to 1500 randomly chosen
general practitioners. The company advised us that
this would probably produce 100 responses, but in
fact 790 (53%) general practitioners responded.
Cancer nurses-Questionnaires were circulated
randomly to 1000 of the 3500 members of the Royal
College ofNursing Oncology Nursing Society, and 303
(30%) responded.
Differences in proportions of subjects opting for
each preference among the different groups were
tested for significance using the x2 test. Median scores
were produced for each group as a summary statistic.
Results
Table I shows the median scores for each group for
the intensive and mild treatments. The scores repre-
sented the minimal benefit that would make treatment
acceptable to the subjects, the range for all groups
being from the minimum acceptable to unacceptable.
Substantial differences were shown between the
patients who had cancer and every other group. Most
importantly, the patients with cancer gave very
different results from the matched control group for
both treatments in all circumstances. In general, the
patients were most likely to accept intensive treatments
for a potentially small benefit whereas the control
group were least likely to accept intensive treatment
and wanted the most benefit for any particular risk.
After completing three months of treatment the
responses of the 50 patients who completed the
questionnaire a second time changed negligibly. No
significant difference was shown when the first and
second responses were compared for the intensive and
the mild treatments, whether or not the patient had
actually received an intensive or a milder treatment.
The responses of the medical oncologists, general
practitioners, and cancer nurses fell between those of
the patients and controls, with medical oncologists
being more likely to accept radical treatments than
general practitioners, who in turn were more likely to
accept them than cancer nurses. Radiotherapists were
the least likely of any group to accept treatment.
Table II shows the percentage of subjects in each
group who would accept the intensive and mild
treatments given minimal benefit for each category
for cure, prolonging life, or relief of symptoms. It
illustrates the dramatic difference between the patients
and all other groups. Significantly more patients
accepted treatments with much less benefit than
any other group (p<0001), and the radiotherapists
required more benefit from the treatments than any
other group (p<0-01).
Discussion
Presenting patients with treatment options is a
complex and difficult process. On the one hand
patients need sufficient information to allow them to
make an informed decision, but on the other hand the
doctor does not want to remove all hope and demoralise
the patient. Thus most patients treated in a centre that
specialises in the treatment of cancer are given infor-
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TABLE iI-Respondents accepting intensive and mild treatments with a supposed minimum chance of
effectiveness by subject group
Subject group
General
Controls Cancer nurses practitioners Radiotherapists Oncologists Patients
(Cure (I%)
Intensive treatment:
Total respondents 100 300 790 88 60 96
No(%)ofrespondentsaccepting 19 41(13 5) 98(12 4) 4(4-5) 12(20-0) 51(53-1)
treatment
Mild treatment:
Total respondents 100 302 788 88 60 94
No(%)ofrespondentsaccepting 35 118(38-9) 349(44-3) 24(27 3) 31 (51-7) 63(67-0)
treatment
Prolonging life (bv three months)
Intensive treatment:
Total respondents 100 302 790 86 60 95
No(%)ofrespondentsacccpting 10 18 (6-0) 26(3-3) 0 6(10-2) 40(42 1)
treatment
Mild treatment:
Total respondents 100 303 788 87 60 93
No (%) of respondents accepting 25 77(25 4) 215 (27-3) 11 (12-6) 27(45-0) 50(53-0)
treatment
Reliefofsvmptoms (1%)
Intensive treatment:
Total respondents 100 303 790 87 60 94
No (%) of respondents accepting 10 (10) 18 (5-9) 19 (2-4) 0 4 (6-8) 40 (42-6)
treatment
Mild treatment:
Total respondents 100 303 789 88 60 92
No (%) of respondents accepting 19 (19) 80 (26-4) 167 (21-2) 2 (2-3) 7 (11-7) 54 (58-7)
treatment
mation about their diagnosis and details about the
treatment. They are told whether the aim of treatment
is to cure the cancer or to control it, but seldom are
patients given statistics and likelihoods to help them
make their decisions. This information is usually given
only if the patient asks for it. A hypothetical framework
was specifically chosen for this study to avoid demoral-
ising the patients and to prevent them thinking that
their answers to the questions would influence their
treatment.
All the patients who were given the questionnaire,
however, knew that they were about to receive
chemotherapy and thus considered the questions
seriously. This group thus excluded those patients for
whom chemotherapy was an unacceptable treatment
option because they would not have been referred to
the unit. To this extent the group was not representa-
tive of an entire population of patients with cancer.
There are no numbers available about the percentage
of all patients with cancer who would decline chemo-
therapy if offered. In clinical practice, however, only a
small proportion of patients with cancer refuse chemo-
therapy, and the numbers are therefore probably close
to those that would be obtained in an unselected
sample of patients with cancer. The patients' responses
were compared with those of a matched control group
without cancer. This control group was carefully
matched for age and sex, as well as for occupation and
hence educational and social class. It was therefore
hoped that the attitude of the control group would
represent that of the patient group before they had
developed cancer. The large differences that emerged
between these two groups suggest that patients'
attitudes to treatment change dramatically when they
are given the diagnosis ofcancer. Faced with the reality
of the diagnosis, as opposed to the purely theoretical
possibility, patients are likely to accept any treatment
that offers them some possible benefit and hope,
however slight. It suggests that people with cancer find
it difficult to accept circumstances in which there are
no therapeutic options, and it might be argued that
their response represents a feeling of panic in a crisis.
Thus when asked about relief of symptoms 43% of the
patients accepted intensive treatment when the chance
of relief was very small.
Although doctors may have the facts and statistics
available they inevitably make subjective judgments
in recommending a particular treatment option to
patients. Assessments of patients' quality of life and
their levels of anxiety and depression by doctors and
nurses correlate poorly with those made by the patients
themselves.7 This study illustrates how difficult it is to
suggest that doctors and nurses should be, or indeed
are, in a position to advise patients what treatment to
have based on what they might want in a similar
situation. Firstly, different groups of doctors and
nurses had significantly different views of what they
would accept for themselves. Secondly, there was a
wide variability within individual groups. It is interest-
ing to note the large differences between the two
groups of cancer specialists, with the medical oncolo-
gists having a more optimistic view of the benefit
of chemotherapy than the radiotherapists, who repre-
sented the most pessimistic group (table II). The
radiotherapists' response has to be taken with a
degree of caution because of the low rate of reply
(37%) compared with that of the oncologists (78%),
(p<O0OOOl). The same caveat applies to the responses
of the nurses. It is often said that doctors are over-
enthusiastic about offering patients intensive treatment
when the chance of benefit is small, but these data
suggest that the patients themselves were considerably
more enthusiastic than their doctors.
The patients with cancer appeared to regard a
minute chance of possible benefit as worth while,
whatever the cost. It would be easy to conclude that
this is an irrational decision resulting from the tre-
mendous stress imposed on these patients by their
disease. This is by no means clear, however; it may be
that the only people who can evaluate such life and
death decisions are those faced with them.
The patients' responses in this study suggest that a
high degree of toxicity is acceptable, even if only a
slight chance of cure is offered. It seems probable that
this value cannot be appreciated when a person is well
and that attitude changes appreciably when a person is
faced with what is perceived as a life threatening
disease.
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ANY QUESTIONS
Are there any lasting physical consequences ofcompetitive swimming?
Provided the person is physically fit there are no lasting consequences of
competitive swimming. Most of the problems related to aquatic sports are
caused outside competitions, and the only lasting physical consequences
are related to competing in an unfit state or before a swimming problem
has resolved. This is commonly seen when individuals persist with
competitive swimming following such conditions as stress fractures of the
pars interarticularis and chronic shoulder injuries such as occur in
butterfly swimmers. In water polo, however, like any other contact sport,
there may be some residual disability from damaged fingers, etc, when the
athlete persists in competing before complete healing has occurred. -J M
CAMERON, professor offorensic medicine and honorary medical adviser to the
Amateur Swimming Association
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